Resistance to therapy remains a significant challenge in the treatment of lung cancer, leading to decreased treatment effectiveness and poorer outcomes for patients. Despite advancements in treatment modalities such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, resistance mechanisms driven by genetic mutations, epigenetic changes, and alterations in the tumor microenvironment persist. Understanding these mechanisms is crucial for developing strategies to overcome therapeutic resistance and improve patient outcomes. This review explores the current landscape of therapeutic resistance in lung cancer and promising strategies to combat this resistance.
Lung cancer, a leading cause of cancer-related deaths globally, is a molecularly heterogeneous disease with two major subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). While treatment options have evolved over the years, resistance to therapies remains a significant hurdle. Genetic mutations in driver genes like KRAS, EGFR, and TP53 contribute to treatment resistance, highlighting the importance of targeted therapies. Efforts to classify lung cancers based on genetic lesions have guided the development of targeted therapies, improving clinical outcomes for patients with specific mutations.
Chemotherapy, a standard treatment option for advanced lung cancer, faces challenges due to the development of chemoresistance mechanisms. Factors contributing to chemoresistance include changes in drug influx/efflux, alterations in DNA repair pathways, and signaling pathway activation. Understanding these mechanisms has led to the exploration of novel targets like glutathione S-transferase isozymes and signal transduction pathways to enhance the effectiveness of chemotherapy. Moreover, interventions targeting lysosomal function and autophagy have shown promise in sensitizing cancer cells to chemotherapy, offering potential strategies to combat resistance.
Radiotherapy, a mainstay in lung cancer treatment, can also encounter resistance mechanisms that reduce treatment efficacy. Pro-survival and metastatic signaling pathways, genetic alterations, and redox imbalance contribute to radioresistance in lung cancer. Strategies targeting these pathways, such as inhibiting PI3K/AKT signaling or modulating ROS levels, have shown potential in sensitizing cancer cells to radiotherapy. Additionally, understanding the role of EMT in radioresistance has led to the identification of specific targets like CXCR4 and TESC, offering avenues for overcoming resistance in lung cancer.
Targeted therapies directed at oncogenic driver alterations have revolutionized lung cancer treatment, particularly in patients with EGFR and ALK mutations. However, the emergence of resistance mechanisms poses a challenge to their long-term effectiveness. Novel approaches like allosteric kinase inhibitors, targeting GRB2 or EHMT2, and regulating heme levels have shown promise in overcoming EGFR TKI resistance. Insights into EGFR-independent resistance mechanisms, such as MET and HER2 amplification, have also paved the way for innovative strategies like HIF-1 inhibition to combat resistance in lung cancer.
In conclusion, the landscape of therapeutic resistance in lung cancer is complex and multifaceted, driven by a variety of genetic, epigenetic, and microenvironmental factors. Overcoming this resistance requires a comprehensive understanding of the underlying mechanisms and the development of targeted strategies to resensitize cancer cells to treatment. By exploring novel targets and innovative approaches, researchers and clinicians aim to improve patient outcomes and prolong survival in lung cancer.
Tags: clinical trials, adjuvants, regulatory, downstream, immunotherapy
Read more on pmc.ncbi.nlm.nih.gov